Harvard scientist Charles Lieber seeks acquittal in 'ill-conceived' China Initiative case

Nicole DeFeudis

Editor

Years after getting swept up in the controversial Trump-era “China Initiative” — and months after being convicted on six felony charges — notable Harvard scientist Charles Lieber …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Harvard scientist Charles Lieber seeks acquittal in 'ill-conceived' China Initiative case

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Har­vard sci­en­tist Charles Lieber seeks ac­quit­tal in 'ill-con­ceived' Chi­na Ini­tia­tive case

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Harvard scientist Charles Lieber seeks acquittal in 'ill-conceived' China Initiative case

Applied Therapeutics' rare disease drug gets a CRL

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role